Skip to main content
36°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adicet Bio, Inc. - Common Stock
(NQ:
ACET
)
0.9919
+0.0924 (+10.27%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adicet Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
January 10, 2023
Tuesday's session saw 16 companies set new 52-week lows.
Via
Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Peering Into Adicet Bio's Recent Short Interest
December 13, 2022
Adicet Bio's (NASDAQ:ACET) short percent of float has risen 29.62% since its last report. The company recently reported that it has 4.02 million shares sold short, which is 12.56% of all regular shares...
Via
Benzinga
Dow Surges Over 250 Points; Weber Shares Spike Higher
December 12, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday
Via
Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
December 12, 2022
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
Via
Benzinga
Stocks Hold Gains Ahead Of Tuesday's Economic Flurry
December 12, 2022
The major indexes are continuing their move higher this afternoon, as investors await tomorrow's release of November's consumer price index (CPI) data.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
December 12, 2022
Via
Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
December 12, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Adicet Bio Shares Fall After Underwhelming Data From Non-Hodgkin's Lymphoma Study
December 12, 2022
Via
Benzinga
US Stocks Higher; Dow Rises Over 100 Points
December 12, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday
Via
Benzinga
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
December 12, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 12, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 12, 2022
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!
Via
InvestorPlace
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 10, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 02, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
November 29, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Target, Holley, Ferroglobe And Other Big Losers From Wednesday
November 17, 2022
U.S. stocks closed mostly lower on Wednesday, with the Nasdaq Composite dropping around 175 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
November 17, 2022
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Via
Benzinga
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
November 03, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
November 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022
From
Adicet Bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 25, 2022
Gainers Taysha Gene Therapies (NASDAQ:TSHA) stock increased by 36.4% to $2.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $84.6 million.
Via
Benzinga
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Adicet Bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.